Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …

Chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of several
antineoplastics. It can lead to detrimental dose reductions and discontinuation of treatment …

Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling pain condition resulting
from chemotherapy for cancer. Severe acute CIPN may require chemotherapy dose …

Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing
impact as oncological treatments, using potentially neurotoxic chemotherapy, improve …

This review provides an update on the current clinical and preclinical understanding of
chemotherapy induced peripheral neuropathy (CIPN). The overview of the clinical syndrome …

Wallerian axon degeneration is a form of programmed subcellular death that promotes axon
breakdown in disease and injury. Active degeneration requires SARM1 and MAP kinases …

Chemotherapy-induced peripheral neuropathy (CIPN) is a disruptive and persistent side
effect of cancer treatment with paclitaxel. Recent reports showed that paclitaxel treatment …

As there are increasing numbers of cancer survivors, more attention is being paid to the long
term unwanted effects patients may experience as a result of their treatment and the impact …

Chemotherapy-induced peripheral neuropathic pain (CIPNP)—a severe adverse effect
observed in up to 80% of patients during treatment with antineoplastic drugs—limits the …

Commonly used chemotherapeutic agents in oncology/hematology practice, causing toxic
peripheral neuropathy, include taxanes, platinum compounds, vinca alkaloids, proteasome …